New osteoporosis drug combination outperforms current alternatives

May 14, 2013

A combination of two FDA-approved osteoporosis drugs with different mechanisms of action was found to increase bone density better than treatment with either drug alone in a small clinical trial. As reported in paper receiving Online First publication in The Lancet, Massachusetts General Hospital (MGH) investigators found that treatment combining denosumab (Prolia) and teriparatide (Forteo) was superior to single-agent treatment in a 12-month trial in women with postmenopausal osteoporosis. The authors note that additional study is required before their findings should be put into clinical practice.

"We found that giving both of these drugs together increased more than treatment with just one drug and more than has been reported for any currently available therapy for postmenopausal osteoporosis," says Benjamin Leder, MD, of the MGH Endocrine Unit, corresponding author of the Lancet report. "This is particularly important since previous attempts to combine with like Fosamax did not show any additional improvement."

Bone density in young adults is maintained by a constant interaction between cells called , which break down bone, and osteoblasts, that form new bone. After a woman goes through menopause, both processes accelerate, but the breakdown or resorption of bone increases more, leading to the overall loss of bone density and osteoporosis, a thinning of the bones leading to increased risk of fractures. While several types of drugs that increase bone density – teriparatide, which stimulates bone formation, and several that block – have been approved for the treatment of postmenopausal osteoporosis, none can reliably restore normal in most patients or eliminate osteoporosis-related .

Previous trials combining teriparatide with , which block breakdown, did not show improvement over treatment with a single drug. But some animal studies combining teriparatide with denosumab, which blocks resorption using a different mechanism, suggested a possible benefit, leading the MGH team to design the current trial. They enrolled 100 postmenopausal women determined to be at high fracture risk, based on their bone density and other risk factors, who were randomly divided into three groups.

Over the 12-month study period, one group received a subcutaneous 60 mg dose of denosumab every six months, another group self-administered daily 20-microgram injections of teriparatide, and the third received both drugs at the same dosage schedules. Bone density and blood tests were taken at the outset of the study and after 3, 6 and 12 months, and the final analysis included 94 participants who completed at least one follow-up visit.

Participants receiving treatment with both drugs had significantly better results than those receiving just one at several measured sites. For example, bone density measured at the lumbar spine increased 6.2 percent with teriparatide alone and 5.5 percent with denosumab, but combination treatment resulted in a 9.1 percent increase. Similar bone density improvements were seen at the hip.

In considering possible reasons for this combination's superiority over combined bisphosphonate and teriparatide, Leder explains that teriparatide actually stimulates both bone formation and resorption and that denosumab may more completely block teriparatide-induced resorption while only partially interfering with the drug's stimulation of . An associate professor of Medicine at Harvard Medical School, he notes that longer studies are required in larger groups of patients to assess the combination's ability to reduce fracture risk and its long-term safety.

Explore further: Teriparatide ups bone union for women with osteoporosis

More information: … (13)60856-9/abstract

Related Stories

Teriparatide ups bone union for women with osteoporosis

November 3, 2012
(HealthDay)—Injections of teriparatide are more effective than oral bisphosphonate for bone union after instrumented lumbar posterolateral fusion in women with postmenopausal osteoporosis, according to a study published ...

Teriparatide injections improve pedicle bone quality

May 2, 2013
(HealthDay)—Daily injection of teriparatide significantly reduces the incidence of pedicle screw (PS) loosening at one year following surgery to correct degenerative spondylolisthesis in osteoporotic postmenopausal women, ...

Common osteoporosis drug slows formation of new bone

April 17, 2013
Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal ...

Yearly zoledronic acid at lower-than-standard doses increases bone density

June 6, 2011
A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic ...

Mechanisms for a beneficial effect of moderate alcohol consumption on osteoporosis in women

August 2, 2012
Women after menopause tend to develop weaker bones from what is known as osteoporosis, which may lead to fractures (especially hip fractures) from falling. The weakness of the bones results from an imbalance between the normal ...

Primary care physicians vital to complete care of prostate cancer patients

May 14, 2013
Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment. A new study¹ by Vahakn ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.